Faisal Fakih

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial

William W. Busse, Eugene R. Bleecker, J Mark FitzGerald et al. · The Lancet Respiratory Medicine · 2018 · 311 citations

Pharmacy, Pharmacology, Pharmacotherapy +6

Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial

John A. Smith, Michael M. Kitt, Alyn H. Morice et al. · The Lancet Respiratory Medicine · 2020 · 224 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial

Tim Harrison, Pascal Chanez, Francesco Menzella et al. · The Lancet Respiratory Medicine · 2020 · 175 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +15

Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study

Andrew Menzies‐Gow, Michael E. Wechsler, Christopher E. Brightling et al. · The Lancet Respiratory Medicine · 2023 · 141 citations · Full text

Life Sciences, Immunology, Internal Medicine +13